Experience in Use of Dabigatran at Knee Arthroplasty
Elena Viktorovna Reyno , T A Zhairova , N L Kuznetsova , I P Antropova , E V Reino , T A Zhirova , I P Antropova
N.N. Priorov Journal of Traumatology and Orthopedics ›› 2011, Vol. 18 ›› Issue (3) : 54 -58.
Experience in Use of Dabigatran at Knee Arthroplasty
Primary knee arthroplasty under combined spinal epidural anesthesia (CSEA) was performed to 30 patients with III stage of gonarthrosis. Anticoagulant prophylaxis of venous thromboembolism was started 12 hours prior to surgery - subcutaneous injections of 40 mg enoxaparine sodium (Clexane®). Postoperatively all patients were taken direct inhibitor of thrombin - dabigatran etexilate (Pradaxa®) by standard scheme: 110 mg in 3 hours after operation and than 220 mg once a day for 14 days. Deep vein thrombosis (DVT) was diagnosed in 2 cases (6.7% of patients). This rate was not higher than in case of prophylaxis with low molecular weight heparins. No hemorrhagic complications were noted. Maximum growth of total coagulation index was observed on 3 - 7 days after surgery that was manifested by raise of fibrinogen concentration, soluble fibrin-monomer complexes (SFMC) and increased activity of coagulation enzymic link. Indices returned to norm by 14th postoperative day. Use of dabigatran etexilate in knee arthroplasty provides an adequate prophylaxis of venous thromboembolism and does not increase the risk of hemorrhagic complications.
knee arthroplasty / deep vein thrombosis / hemostasis / anticoagulants / pro-phylaxix of thromboembolic complications / anticoagulants / low molecular weight heparins / dabigatran etexilate
| [1] |
Балуда В.П., Балуда М.В., Гольдберг А.П. и др. Претромботическое состояние. Тромбоз его профилактика. - М., 1999. |
| [2] |
Кириенко А.И., Андрияшкин В.В. Стратегия профилактики острых венозных тромбозов у хирургических больных //Трудный пациент. - 2004. - N 5. - С. 3-7. |
| [3] |
Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений //Флебология. - 2010. - N 1. - С. 22-23. |
| [4] |
Стуров Н.В., Моисеев С.В. Клиническая фармакология дабигатрана - представителя нового класса антикоагулянтов - прямых ингибиторов тромбина //Клин. фармакол. и тер. - 2009. - N 5. - С. 32-37. |
| [5] |
Clagett G.P., Anderson F.A.Jr., Geerts W. et al. Prevention of venous thromboembolism //Chest. - 1998. - Vol. 114. - P. 531-560. |
| [6] |
Eriksson B.I., Kдlebo P., Anthymyr B.A. et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement: comparison of low-molecular-weight heparin and unfractionated heparin //J. Bone Jt Surg. - 1991. - Vol. 73. - P. 484-493. |
| [7] |
Ettema H.B., Hoppener M.R., Bьller H.R. et al. Thrombosis prophylaxis in orthopaedic surgery: considerations and uncertainties //Ned Tijdschr Geneeskd. - 2003. - Vol. 147, N 38. - P. 1842-1847. |
| [8] |
Hirsh J. Evidence for the needs of out-of-hospital thrombosis prophylaxis: introduction //Chest. - 1998. - Vol. 114. - P. 113-114. |
| [9] |
Nicolaides A., Arcelus J., Belcaro G. et al. Prevention of venous thromboembolism //Int. Angiol. - 1992. - N 11. - P. 151-159. |
Eco-Vector
/
| 〈 |
|
〉 |
PDF
